Evidence map›Paper›PMID 41666885›Full record

ArticleClinical practice and cases in emergency medicine2026

Recurrent Miller Fisher Syndrome: A Case Report.

Larry Vernier, Griffin Barnes Gilmore, Kelsey Van Housen, Xiao Chi Zhang

Abstract readCase Reports
In one paragraph

Article in Clinical practice and cases in emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Larry VernierMontefiore Einstein, Department of Emergency Medicine, The Bronx, New York.
Griffin Barnes GilmoreMount Sinai Elmhurst, Department of Emergency Medicine, Queens, New York.
Kelsey Van HousenSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Xiao Chi ZhangThomas Jefferson University, Department of Emergency Medicine, Philadelphia, Pennsylvania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGuillain-Barré syndrome can manifest with progressive paralysis, requiring careful monitoring and treatment with steroids or intravenous (IV) immunoglobin. While this disease can be devastating and require intensive care unit level of care, there are few incidences of relapses. CASE REPORT: A 67-year-old man with a past medical history of Miller Fisher syndrome variant of Guillain-Barré syndrome, with complete recovery, presented to the emergency department (ED) with ataxia, ophthalmoplegia, dysphonia, and ambulatory dysfunction. The patient noticed his neurologic symptoms after waking up, and he presented to the ED with physical examination positive for difficulty with upward gaze, mild right lower facial droop, dysmetria with left finger to nose testing, and unsteady gait. A lumbar puncture revealed albuminocytologic dissociation (an elevated cerebrospinal fluid protein count without elevation in white blood cell count) and he was diagnosed with recurrent Miller Fisher syndrome. The patient completed a five-day course of IV immunoglobin with marked improvement of his symptoms. Unfortunately, the patient continued to have ambulatory difficulty, requiring inpatient rehabilitation with residual deficits including ophthalmoplegia and mild dysphonia.

conclusionMiller Fisher syndrome is an uncommon variant of Guillain-Barré syndrome with atypical neurologic findings that can lead to respiratory distress; it requires high levels of suspicion and diagnostic evaluation. This disease process can recur in a patient's lifetime, contrary to what has been reported in the literature.

Identifiers

PMID41666885
PMCPMC12890356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.